Enovis (NYSE:ENOV) Stock Price Up 5.6% – What’s Next?

Enovis Corporation (NYSE:ENOV)’s share price rose 5.6% on Thursday . The stock traded as high as $27.15 and last traded at $27.0330. 33,723 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,083,448 shares. The stock had previously closed at $25.59.

Analysts Set New Price Targets

Several equities research analysts recently commented on ENOV shares. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Wells Fargo & Company lowered their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. BMO Capital Markets assumed coverage on shares of Enovis in a research note on Wednesday, July 8th. They set an “outperform” rating and a $29.00 target price on the stock. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. Finally, Zacks Research downgraded Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis currently has an average rating of “Moderate Buy” and an average price target of $41.71.

Enovis Stock Down 3.6%

The business’s 50 day simple moving average is $23.52 and its 200-day simple moving average is $23.79. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -1.36 and a beta of 1.39.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same period in the prior year, the business posted $0.81 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis Corporation will post 3.12 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. The trade was a 2.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 4,200 shares of company stock valued at $92,084. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Arax Advisory Partners bought a new stake in shares of Enovis in the fourth quarter valued at about $29,000. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. GAMMA Investing LLC grew its position in Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after acquiring an additional 1,446 shares during the period. Danske Bank A S acquired a new position in Enovis during the third quarter worth $64,000. Finally, iSAM Funds UK Ltd bought a new position in shares of Enovis during the third quarter valued at $80,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.